An interventional study of Albuterol Sulfate inhalation aerosol 108mcg per actuation and Proair HFA (albuterol sulfate) Inhalation Aerosol 90 mcg per actuation in Healthy, sponsored by Intech Biopharm Ltd.. Completed at 1 site in Taiwan. Open to participants aged 20 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-03-18.
Sponsored by Intech Biopharm Ltd. · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study was designed to assess the bioequivalence between the test products (Albuterol Sulfate Inhalation Aerosol 108 mcg Per Actuation) and the reference products (Proair HFA [Albuterol Sulfate] Inhalation Aerosol 90 mcg Per Actuation) in healthy volunteers under fasting conditions. The test product was considered bioequivalent to the reference product if the T/R ln-transformed AUC(0-t), AUC(0-inf), and Cmax were within 80.00-125.00% of those of the reference.
A single-dose, randomized, open-label, two-period, two-sequence, two-treatment, single-centre, crossover bioequivalence study was carried out under fasting conditions in healthy adults, aged 20-60 years. For each period, each subject received a single dose as equivalent to 180 mcg of albuterol of the study drugs according to the pre-determined randomization scheme. Each subject was drawn 22 times over the period of 24 hours. Plasma samples were collected and analyzed for albuterol concentrations by using LC-MS/MS. For each subject, there were 2 dosing periods separated by a 14-day washout period. During the study, standardized meals were provided to all subjects while institutionalized.
Intech Biopharm Ltd. is the lead sponsor of 11 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Subjects must fulfill at least one of the following:
Exclusion Criteria:
Known history or presence of:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Albuterol Sulfate inhalation aerosol
Drug: Albuterol Sulfate inhalation aerosol 108mcg per actuation
Proair HFA (albuterol sulfate) Inhalation Aerosol
Drug: Proair HFA (albuterol sulfate) Inhalation Aerosol 90 mcg per actuation
MDI, 2 puffs, single dose, fasting
Also known as: Albuterol 90mcg/puff
MDI, 2 puffs, single dose, fasting
Also known as: Albuterol 90mcg/puff
Cmax
The maximal observed plasma concentration of Albuterol Sulfate.
Time frame: 0 hour (pre-dose), as well as at 2, 5, 10, 15, 20, 30, 45 minutes, and 1, 1.25, 1.5, 1.75, 2, 2.25, 2.5, 3, 4, 6, 8, 12, 16 and 24 hours post-dose
AUC(0-t)
Area under the concentration time curve from time zero until the last measurable concentration or last sampling time t, whichever occurs first.
Time frame: 0 hour (pre-dose), as well as at 2, 5, 10, 15, 20, 30, 45 minutes, and 1, 1.25, 1.5, 1.75, 2, 2.25, 2.5, 3, 4, 6, 8, 12, 16 and 24 hours post-dose
AUC(0-inf)
Area under the concentration time curve from time zero to infinity.
Time frame: 0 hour (pre-dose), as well as at 2, 5, 10, 15, 20, 30, 45 minutes, and 1, 1.25, 1.5, 1.75, 2, 2.25, 2.5, 3, 4, 6, 8, 12, 16 and 24 hours post-dose
Tmax
Time when the maximal plasma concentration is observed.
Time frame: 0-24 hours
T1/2
Terminal elimination half-life, estimated as ln(2)/λ.
Time frame: 0-24 hours
Kel(λ)
Terminal elimination rate constant, estimated by linear regression analysis of the terminal portion of the ln-concentration vs. time plot.
Time frame: 0-24 hours
Mean Residence Time (MRT)
Mean residence time (MRT) is calculated by the area under the first moment curve dividing by area under the concentration time curve.
Time frame: 0-24 hours
Eighty-four subjects were recruited and screened for the eligibility.
| Milestone | Albuterol Sulfate Inhalation Aerosol First, Then ProairHFA (Albuterol Sulfate) Inhalation Aerosol | Proair HFA (Albuterol Sulfate) Inhalation Aerosol First, Then Albuterol Sulfate Inhalation Aerosol |
|---|---|---|
| Started | 30 | 30 |
| Completed | 30 | 28 |
| Not completed | 0 | 2 |
| Withdrew: Withdrawal by subject | 0 | 1 |
| Withdrew: Protocol violation | 0 | 1 |
The maximal observed plasma concentration of Albuterol Sulfate.
| pg/mL | Albuterol Sulfate Inhalation Aerosol | Proair HFA (Albuterol Sulfate) Inhalation Aerosol |
|---|---|---|
| Cmax | 812.477 ± 281.148 | 945.456 ± 359.695 |
Area under the concentration time curve from time zero until the last measurable concentration or last sampling time t, whichever occurs first.
| hr*pg/mL | Albuterol Sulfate Inhalation Aerosol | Proair HFA (Albuterol Sulfate) Inhalation Aerosol |
|---|---|---|
| AUC(0-t) | 4806.319 ± 981.477 | 5090.449 ± 1053.602 |
Area under the concentration time curve from time zero to infinity.
| hr*pg/mL | Albuterol Sulfate Inhalation Aerosol | Proair HFA (Albuterol Sulfate) Inhalation Aerosol |
|---|---|---|
| AUC(0-inf) | 5204.806 ± 1081.862 | 5509.006 ± 1148.747 |
Time when the maximal plasma concentration is observed.
| hr | Albuterol Sulfate Inhalation Aerosol | Proair HFA (Albuterol Sulfate) Inhalation Aerosol |
|---|---|---|
| Tmax | 0.929 ± 1.089 | 0.514 ± 0.529 |
Terminal elimination half-life, estimated as ln(2)/λ.
| hr | Albuterol Sulfate Inhalation Aerosol | Proair HFA (Albuterol Sulfate) Inhalation Aerosol |
|---|---|---|
| T1/2 | 6.928 ± 1.165 | 6.985 ± 1.357 |
Terminal elimination rate constant, estimated by linear regression analysis of the terminal portion of the ln-concentration vs. time plot.
| 1/hr | Albuterol Sulfate Inhalation Aerosol | Proair HFA (Albuterol Sulfate) Inhalation Aerosol |
|---|---|---|
| Kel(λ) | 0.103 ± 0.019 | 0.103 ± 0.021 |
Mean residence time (MRT) is calculated by the area under the first moment curve dividing by area under the concentration time curve.
| hr | Albuterol Sulfate Inhalation Aerosol | Proair HFA (Albuterol Sulfate) Inhalation Aerosol |
|---|---|---|
| Mean Residence Time (MRT) | 8.629 ± 1.202 | 8.474 ± 1.455 |
Collected over Approximately 16 days for each subject.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Test Group | 0/60 (0%) | 0/60 (0%) | 4/60 (6.7%) |
| Reference Group | 0/58 (0%) | 0/58 (0%) | 1/58 (1.7%) |
| Event | Test Group | Reference Group |
|---|---|---|
| HypertriglyceridemiaMetabolism and nutrition disorders | 0/60 | 1/58 |
| Throat infectionInfections and infestations | 1/60 | 0/58 |
| Aspartate aminotransferase (AST) increasedInvestigations | 1/60 | 0/58 |
| Creatinine increasedInvestigations | 1/60 | 0/58 |
| Alanine aminotransferase (ALT) increasedInvestigations | 1/60 | 0/58 |
| Age, Continuous(years) | All Study Participants |
|---|---|
| Mean | 31.9 ± 7.4 |
| Sex: Female, Male(Participants) | All Study Participants |
|---|---|
| Female | 19 |
| Male | 41 |
| Race (NIH/OMB)(Participants) | All Study Participants |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 60 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 0 |
| White | 0 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
| Height(cm) | All Study Participants |
|---|---|
| Mean | 167.8 ± 6.8 |
| Weight(kg) | All Study Participants |
|---|---|
| Mean | 65.5 ± 8.6 |
| Body mass index (BMI)(kg/m^2) | All Study Participants |
|---|---|
| Mean | 23.2 ± 2.2 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Mar 2021 to primary completion in May 2021, 1 month.
Results were first posted in Sep 2023, 2 years 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Albuterol
Intech Biopharm Ltd.